Key facts
- Notable investors include TopoScend Capital, Fuyang Yingke Fund Management, Boji Pharmaceutical Technology, Feixi County Industrial Park Investment Holding (Group), Jointown Pharmaceutical Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Kingmed
- ·The full record, as it builds
Funding rounds
No funding rounds for Kingmed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kingmed
Developer of organoid solutions intended for the pharmaceutical industry. The company offers a product that mainly focuses on the organoid platform, integrates organoid biotechnology with precision medicine, pharmacy, bioengineering, artificial intelligence, and other multidisciplinary technologies to transform products and services, providing customers with valuable and innovative products.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2019
- Employees
- 7
- Website
- kingmedpharm.com/
- Ownership
- Privately Held (backing)
Kingmed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kingmed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kingmed in its N-PORT filings yet. We sweep new filings monthly.